DB-OTO is an experimental gene therapy for otoferlin-related hearing loss developed by Regeneron Pharmaceuticals. It is delivered via adeno-associated virus.Development of an AAV-Based Gene Therapy for Children with Congenital Hearing Loss Due to Otoferlin Deficiency (DB-OTO).
Source: Journal of Hearing Science . 2022, Vol. 12 Issue 1, p76-76. 1/4p.
Author(s): De Raeve, L.; Holcomb, M.; Ramos MacĂas, A.
|
|